Revvity to Present at J.P. Morgan Healthcare Conference
Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery
Revvity (NYSE:RVTY) was downgraded by analysts at Bank of America Corporation from a "buy" rating to a "neutral" rating. They now have a $110.00 price target on the stock.
Revvity (NYSE:RVTY) was given a new $107.00 price target on by analysts at Wells Fargo & Company.
Revvity (NYSE:RVTY) had its "overweight" rating reaffirmed by analysts at Barclays PLC.